Printer Friendly

Browse Lung cancer, Non-small cell topic

Articles

1-300 out of 600 article(s) nextnext page
Title Author Type Date Words
Effect of Intensity Modulated Radiotherapy (IMRT) on the immunity, physical status and clinical effect of locally advanced NSCLC patients. Jun-kai Xu Oct 22, 2021 3118
FDA approves Genentech's Tecentriq as adjuvant treatment for NSCLC. Oct 15, 2021 192
Turning Point, EQRx team to evaluate elzovantinib/aumolertinib combo in NSCLC. Oct 13, 2021 233
Black Diamond presents preclinical data on BDTX-1535, BRAF, FGFR programs. Oct 8, 2021 224
Mirati, Sanofi to collaborate on adagrasib-SHP2 Inhibitor combo. Oct 7, 2021 173
Turning Point presents updated preliminary clinical data for repotrectinib. Oct 7, 2021 307
Turning Point presents updated preliminary clinical data for elzovantinib. Oct 7, 2021 484
Turning Point Therapeutics provides regulatory update. Oct 7, 2021 325
NCI selects ImmunityBio's receptor agonist Anktiva -Keytruda combo for NSCLC. Oct 4, 2021 197
Lantern Pharma and Lens announce strategic collaboration. Sep 28, 2021 174
Iovance Biotherapeutics initiates clinical supply of TIL cell therapy. Clinical report Sep 23, 2021 250
Onconova announces preliminary data from Phase 1/2a trial of oral rigosertib. Sep 22, 2021 222
Sanofi reports Libtayo Phase 3 trial met primary, key secondary endpoints. Sep 20, 2021 228
Mirati Therapeutics announce Phase 2 topline results for adagrasib. Financial report Sep 20, 2021 277
BeyondSpring announces Phase 3 DUBLIN-3 study met primary endpoint. Sep 20, 2021 365
Mirati Therapeutics announces results from Phase 2 study of MRTX-500. Sep 20, 2021 238
New data support benefits of Genentech's Tecentriq in early-stage NSCLC. Sep 20, 2021 191
AstraZeneca presents data from Phase II DESTINY-Lung01 trial of ENHERTU. Sep 19, 2021 221
Spectrum presents results from Cohort 4 of ZENITH20 clinical trial. Sep 19, 2021 296
Gritstone announces dosing of patient in Phase 2 clinical trial of SLATE. Sep 17, 2021 421
AstraZeneca presents results from COAST trial at ESMO. Sep 17, 2021 425
AstraZeneca says Imfinzi combo improves clinical outcomes in COAST Phase 2 study. Sep 17, 2021 214
Bionano Genomics announce study finding OGM, NGS aids with detecting SVs. Report Sep 16, 2021 303
People urged to try finger test at home which can reveal early signs of lung cancer; The simple test can show if you have finger clubbing -the swelling and softening of fingers and nails -and can be a sign of several underlying health conditions, according to Cancer Research UK. By, Alahna Kindred Sep 14, 2021 333
Purple Biotech to present overview of ongoing Phase 1b/2 trial of CM24. Sep 13, 2021 378
BeyondSpring reports Q2 EPS (49c), consensus (33c). Financial report Sep 10, 2021 212
Thermo Fisher's Oncomine Dx Target Test receives approval by Japan MHLW. Sep 10, 2021 159
Advaxis reports Q3 EPS (2c) vs. (9c) last year. Financial report Sep 10, 2021 171
AstraZeneca announces results from POSEIDON Phase III trial. Sep 9, 2021 423
Hutchmed and AstraZeneca initiate Phase III trial of combination for lung cancer. Sep 8, 2021 158
Covid's cancer vaccine spinoff. MARTIN BAGOT Health Editor Sep 3, 2021 228
Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma. Ekin, Zübeyde; Nart, Deniz; Savas, Pinar; Veral, Ali Report Sep 1, 2021 6354
BeyondSpring announces presentation of Phase 3 DUBLIN-3 data. Aug 31, 2021 225
Conference discusses advances in lung cancer treatment. Conference news Aug 29, 2021 477
BeyondSpring enters commercialization agreement with Hengrui for plinabulin. Aug 26, 2021 317
Compugen's COM902-derived antibody to enter clinical development. Aug 19, 2021 165
Junshi, Coherus Biosciences announce 'positive' interim results in phase 3 trial. Aug 19, 2021 220
Biocept says study shows CNSide detected tumor cells in lung cancer patients. Aug 19, 2021 248
Coherus Biosciences, Junshi announces 'positive' interim CHOICE-01 results. Aug 18, 2021 217
OncoCyte launches first real-world evidence registry. Aug 17, 2021 172
F-star Therapeutics announces expanded development strategy for FS118. Aug 12, 2021 222
Sanofi says Phase 3 Libtayo combo trial stopped early due to improvement in OS. Aug 5, 2021 185
NextCure reports Q2 EPS (65c), consensus (61c). Financial report Aug 5, 2021 159
BeyondSpring announces results from its DUBLIN-3 registrational trial. Financial report Aug 4, 2021 326
Jacobio Pharmaceuticals doses first China patient in JAB-21822 trial. Aug 3, 2021 177
Jacobio Pharmaceuticals doses first China patient in JAB-21822 trial. Aug 3, 2021 176
Hutchmed reports first commercial sale of Orpathys is China, triggers milestone. Jul 13, 2021 152
Immutep expects to report further TACTI-002 data in 2021/early 2022. Jul 13, 2021 152
Eucure Biopharma's YH001 and YH003 receive US FDA phase II clinical trial approval. Jul 7, 2021 258
Eucure Biopharma's YH001 and YH003 receive US FDA phase II clinical trial approval. Jul 7, 2021 257
Agenus closes $200M upfront BMS collaboration, announces FDA acceptance of IND. Jul 6, 2021 236
Achilles Therapeutics enroll first patient in ongoing Phase I/IIa study in NSCLC. Jul 1, 2021 279
Aileron Therapeutics announces initiation of trial of ALRN-6924. Jul 1, 2021 322
Knockdown of Myeloid Cell Leukemia-1 by MicroRNA-101 Increases Sensitivity of A549 Lung Cancer Cells to Etoposide. Shahverdi, Mahshid; Amri, Jamal; Karami, Hadi; Baazm, Maryam Jul 1, 2021 5427
Cantargia expands development of nadunolimab in additional cancers. Jun 29, 2021 232
Cantargia expands development of nadunolimab in additional cancers. Jun 29, 2021 231
Cantargia expands development of nadunolimab in additional cancers. Jun 29, 2021 233
Carmot to Receive Royalty Payments Upon Sales of Amgen's FDA Approved First-in-class KRAS G12C Inhibitor, Lumakras. Jun 29, 2021 509
Onconova provides update on Phase 1/2a trial of rigosertib-nivolumab combination. Jun 28, 2021 160
Mirati Therapeutics' adagrasib receives US FDA Breakthrough Therapy Designation. Jun 25, 2021 155
Mirati Therapeutics' adagrasib receives US FDA Breakthrough Therapy Designation. Jun 25, 2021 156
Mirati's Adagrasib receives breakthrough therapy designation from FDA. Jun 24, 2021 199
AstraZeneca's Orpathys granted conditional approval in China to treat NSCLC. Jun 23, 2021 154
Arcus says Phase 2 ARC-7 study shows 'encouraging' clinical activity. Clinical report Jun 23, 2021 276
AstraZeneca and HUTCHMED's Orpathys approved in China for lung cancer. Jun 23, 2021 218
AstraZeneca and HUTCHMED's Orpathys approved in China for lung cancer. Jun 23, 2021 217
AstraZeneca and HUTCHMED's Orpathys approved in China for lung cancer. Jun 23, 2021 216
BeiGene doses first patient in Anti-TIGIT Antibody Ociperlimab trial for NSLC. Jun 17, 2021 188
Processa Pharmaceuticals enters into licensing agreement with Ocuphire Pharma. Jun 17, 2021 162
C4 Therapeutics presents preclinical data on CFT8919. Jun 7, 2021 368
Amgen presents Phase 2 CodeBreaK 100 trial results. Jun 4, 2021 259
BeyondSpring first patient dosed in triple combination study. Jun 4, 2021 344
Cullinan announces Phase 1/2a interim data for CLN-081. Jun 4, 2021 459
Heat Biologics to present survival data of HS-110 in NSCLC. Jun 4, 2021 294
Novartis announces first published mature OS data from GEOMETRY mono-1 study. Jun 4, 2021 161
Jounce Therapeutics presents progress on INNATE, SELECT clinical trials. Jun 4, 2021 391
Achilles Therapeutics presents phase I/IIa clinical trial design of CHIRON. Jun 4, 2021 190
Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Yu-jie Cui, Jia Liu, Miao-miao Liu and Hong-zhen Zhang Jun 4, 2021 2834
Effect of Sintilimab combined with Chemotherapy on Tumor Markers and Immune Function of advanced non-small cell lung cancer. Xiaoyan Liang and Zhangfeng Wei Jun 4, 2021 2832
CStone Pharmaceuticals' sugemalimab meets primary endpoint in first-in-class registration clinical trial. Jun 1, 2021 186
CStone Pharmaceuticals' sugemalimab meets primary endpoint in first-in-class registration clinical trial. Jun 1, 2021 187
Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies. Youn, Bora; Wilson, Ira B.; Mor, Vincent; Trikalinos, Nikolaos A.; Dahabreh, Issa J. Report Jun 1, 2021 6247
Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis. Feng, Xu; Xu, En-Shi Report Jun 1, 2021 3791
Amgen's Lumakras receives US FDA approval. May 31, 2021 164
Amgen's Lumakras receives US FDA approval. May 31, 2021 165
AstraZeneca receives EU approval for lung cancer drug Tagrisso. May 29, 2021 319
CStone Pharmaceuticals's sugemalimab meets primary endpoint for stage III lung cancer testing. May 28, 2021 192
CStone Pharmaceuticals's sugemalimab meets primary endpoint for stage III lung cancer testing. May 28, 2021 193
AstraZeneca's Tagrisso gets EU approval for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer. May 28, 2021 231
TOP NEWS: AstraZeneca early-stage lung cancer drug gets EU approval. May 28, 2021 233
AstraZeneca's Tagrisso gets EU approval for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer. May 28, 2021 230
AstraZeneca's Tagrisso gets EU approval for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer. May 28, 2021 229
AstraZeneca's Tagrisso approved in E.U. for NSCLC treatment. May 28, 2021 205
Zai Lab announces first patient treated in China in Phase 2 TRIDENT-1 study. May 28, 2021 227
Oncorus plans to file IND application for ONCR-021 in 2023. May 27, 2021 184
C4 Therapeutics to advance CFT8919 to IND-enabling studies. May 26, 2021 235
Guardant360 CDx Receives FDA Approval as Companion Diagnostic for Janssen's Rybrevant for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. May 26, 2021 416
Regeneron Pharmaceuticals receives positive opinions for Libtayo use in Europe. May 24, 2021 191
Regeneron Pharmaceuticals receives positive opinions for Libtayo use in Europe. May 24, 2021 190
Regeneron, Sanofi receive CHMP recommendation for two Libtayo treatments. May 24, 2021 262
Zai Lab announces first patient treated in Greater China in METIS Phase 3 trial. May 24, 2021 164
Johnson & Johnson's Janssen reports updated Chrysalis study results. May 20, 2021 243
Genentech announces interim results from Phase III IMpower010 study. Clinical report May 19, 2021 244
Novocure receives FDA approval for LUNAR trial IDE supplement. May 18, 2021 195
Novocure Receives FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer. May 18, 2021 458
Vaccinex reports Q1 revenue $850,000. Financial report May 17, 2021 244
Merus new collaborations in Israel, Italy, Spain to increase cancer screenings. May 13, 2021 204
AstraZeneca posts positive final-stage trial results for lung cancer treatment. May 8, 2021 533
Genprex in-licenses additional gene therapy technologies to treat non-small cell lung cancer. May 7, 2021 276
AstraZeneca reports positive results in Phase 3 lung cancer drug trial. Financial report May 7, 2021 209
AstraZeneca Imfinzi demonstrates OS benefit in POSEIDON trial for NSCLC. May 7, 2021 214
Genprex in-licenses gene therapy technologies for lung cancer treatment. May 6, 2021 161
Gritstone Oncology announces anticipated upcoming milestones. Clinical report May 6, 2021 174
Genprex wins centralized Institutional Review Board approval for its Acclaim-1 clinical trial in non-small cell lung cancer. May 6, 2021 403
Genprex initiates site recruitment for Acclaim-2 clinical trial for its lung cancer drug REQORSA. May 5, 2021 254
Heat Biologics reports Q1 EPS (31c), three estimates (29c). Financial report May 5, 2021 191
Lantern Pharma reports Q1 EPS (24c), consensus (27c). Financial report May 3, 2021 208
Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer. Yu, Xiangjing; Liu, Jie; Qiu, Huawei; Hao, Huiting; Zhu, Jinhong; Peng, Shiyun Report May 1, 2021 5794
AstraZeneca's Tagrisso recommended in E.U. for treatment of EGFR lung cancer. Disease/Disorder overview Apr 26, 2021 187
Lantern Pharma's LP-184 candidate shows lung cancer potency in publication. Apr 26, 2021 202
Purple Biotech announces dosing of first patient in Phase 1b/2 trial of CM24. Apr 23, 2021 185
Vaccinex announces publication of results from CLASSICAL-Lung phase 1b/2 trial. Financial report Apr 21, 2021 263
Active Biotech and NeoTX get green light for Phase IIa trial of anti-cancer immunotherapy. Apr 19, 2021 164
Active Biotech and NeoTX get green light for Phase IIa trial of anti-cancer immunotherapy. Apr 19, 2021 163
Active Biotech and NeoTX get green light for Phase IIa trial of anti-cancer immunotherapy. Apr 19, 2021 165
AstraZeneca wins approval in China for early-stage lung cancer treatment Tagrisso. Apr 15, 2021 316
LATEST COMPANY NEWS. Apr 14, 2021 24897
AstraZeneca's Tagrisso approved in China in early lung cancer. Apr 14, 2021 218
Genprex presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting. Apr 13, 2021 529
Genprex targets non-small cell lung cancer and diabetes via gene therapy. Apr 13, 2021 780
Shattuck Labs highlights preclinical data for SL-9258 and GLADEN at AACR 2021. Apr 12, 2021 160
Genprex collaborators report data for REQORSA therapy in NSLC treatment. Apr 12, 2021 173
Turning Point initiates Phase 1/2 Forge-1 study of TPX-0131. Apr 12, 2021 214
BeiGene presents interim analysis results of Rationale 303 trial of tislelizumab. Apr 12, 2021 184
Bristol-Myers announces results from CheckMate -816 study. Apr 11, 2021 274
Spectrum presents additional twice daily dosing data for Poziotinib at AACR. Apr 11, 2021 245
aTyr Pharma presents preclinical research on the effects of ATYR2810. Apr 9, 2021 161
Genprex targets non-small cell lung cancer and diabetes via gene therapy. Apr 7, 2021 773
Bridge Biotherapeutics commences BBT-176 phase one/two clinical trial. Apr 7, 2021 178
Bridge Biotherapeutics commences BBT-176 phase one/two clinical trial. Apr 7, 2021 179
Genprex to present preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting. Mar 31, 2021 415
Provectus receives notice of allowance for patent for PV-10 immunotherapy. Mar 30, 2021 212
Roche's Tecentriq receives positive CHMP opinion as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer. Mar 29, 2021 252
Roche's Tecentriq receives positive CHMP opinion as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer. Mar 29, 2021 251
Aileron Therapeutics reports Q4 EPS (12c), consensus (13c). Financial report Mar 24, 2021 193
Roche hails "landmark" Tecentriq Phase III lung cancer study results. Mar 22, 2021 275
Genentech: Tecentriq met primary endpoint in Phase III Mpower010 study. Mar 22, 2021 311
Purple Biotech initiates Phase 1b/2 trial of CM24. Mar 19, 2021 163
Novartis drug misses primary endpoint in lung cancer trial. Mar 9, 2021 157
'Revolutionary' new cancer treatment builds on COVID-19 jab tech. Arab News Mar 6, 2021 242
China Regulator Accepts Supplemental Biologics License Application for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer. Mar 5, 2021 683
Guardant360 CDx Liquid Biopsy Granted CE Mark for Comprehensive Tumor Mutation Profiling Across All Solid Cancers. Mar 3, 2021 417
Recent advancement on PD-L1 expression quantification: the radiologist perspective on CT-guided FNAC. Casale, Silvia; Bortolotto, Chandra; Stella, Giulia Maria; Filippi, Andrea Riccardo; Gitto, Salvator Report Mar 1, 2021 3869
Prognostic factors in patients undergoing pulmonary resection for sarcomatoid carcinomas of the lung. Ozkan, Berker; Erdogdu, Eren; Duman, Salih; Amirov, Fahmin; Cimenoglu, Berk; Ozliik, Yasemin; Kara, Report Mar 1, 2021 5041
Next generation sequencing detection in archival surgically resected lung adenocarcinoma specimens harbouring the anaplastic lymphoma kinase fusion protein. Jiang Zhiming; Li Chenghui; Lu Hongyang Report Feb 28, 2021 3618
China's administrator approves Harbour BioMed's Investigational New Drug application for HBM4003. Feb 26, 2021 167
China's administrator approves Harbour BioMed's Investigational New Drug application for HBM4003. Feb 26, 2021 163
Biocept teams up with Protean BioDiagnostics to study Target Selector in determining EGFR mutations in tumor samples. Feb 24, 2021 484
Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC). Feb 23, 2021 315
Biocept to present study showcasing its ultra-sensative Target Selector biopsy assay kits at a virtual medical conference this week. Conference news Feb 17, 2021 616
Potential seen for Takeda lung cancer treatment. Feb 15, 2021 537
Imugene doses first patient in cohort-2 in phase-I clinical trial of PD1-Vaxx. Feb 13, 2021 297
Imugene doses first patient in cohort-2 in phase-I clinical trial of PD1-Vaxx. Feb 13, 2021 299
Redx Pharma upbeat as funding rounds underline potential. Feb 9, 2021 449
Genprex forms Clinical Advisory Board to support its oncology and diabetes development programs. Feb 9, 2021 546
NA Proactive news snapshot: Genprex, Great Bear Resources, OTC Markets Group, BioLargo UPDATE ... Feb 9, 2021 3943
IN BRIEF: Angle Says Athens University Study Shows Value Of Parsortix. Feb 8, 2021 303
EMD Serono's TEPMETKO (tepotinib) receives US FDA approval. Feb 4, 2021 165
EMD Serono's TEPMETKO (tepotinib) receives US FDA approval. Feb 4, 2021 169
Innovent Biologics and Eli Lilly's TYVYT in combination with pemetrexed and platinum chemotherapy receives China regulator's supplemental New Drug Application approval. Feb 3, 2021 206
Innovent Biologics and Eli Lilly's TYVYT in combination with pemetrexed and platinum chemotherapy receives China regulator's supplemental New Drug Application approval. Feb 3, 2021 210
4D Pharma Says MRx0518 Part B Study Enrolment Continues To Progress. Feb 3, 2021 320
Genprex full steam ahead toward non-small cell lung cancer trials in 2021, CEO Rodney Varner writes. Feb 2, 2021 362
Positive AstraZeneca Tagrisso Trial Results Regardless Of Cancer Stage. Jan 29, 2021 578
US FDA Accepts Biologics License Application for BAT1706, a Proposed Biosimilar to Avastin. Jan 28, 2021 351
Takeda Pharmaceutical Gets Japan Green Light For Lung Cancer Drug. Jan 22, 2021 170
Genprex's drug REQORSA in cold storage, ready for upcoming combination trials. Jan 20, 2021 151
TOP NEWS: Glaxo And Merck KGaA Discontinue Bintrafusp Alfa Trial. Jan 20, 2021 246
AstraZeneca says EU, UK approve cancer drug for additional dosing option. Jan 16, 2021 336
AstraZeneca's Imfinzi gets EU and UK approval at new dose. Jan 15, 2021 222
AstraZeneca's Imfinzi gets EU and UK approval at new dose. Jan 15, 2021 223
AstraZeneca's Imfinzi gets EU and UK approval at new dose. Jan 15, 2021 218
EU Okays New Dosing Option For Lung Cancer Drug Imfinzi - AstraZeneca. Jan 15, 2021 225
Genprex meets manufacturing requirements for lung cancer drug REQORSA ahead of combination trials. Jan 14, 2021 372
Roche's New Cancer Immunotherapy Gets Green Light From US Regulator. Jan 5, 2021 258
GLOBAL TOP NEWS SUMMARY: Trump Calls On Georgia Voters To Save America. Jan 5, 2021 1510
SMARCA4/BRG1-Defident Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature. Nambirajan, Aruna; Singh, Varsha; Bhardwaj, Nishu; Mittal, Saurabh; Kumar, Sunil; Jain, Deepali Report Jan 1, 2021 6415
BIO-THERA SOLUTIONS AND Biomm MARKET BAT1706 IN BRAZIL. Clinical report Jan 1, 2021 441
Non-Small Cell Lung Cancer: Part II. Lacovara, Jane; Bohnenkamp, Susan Column Jan 1, 2021 1966
IN BRIEF: J&J's Janssen Submits European Application For Amivantamab. Dec 28, 2020 197
Amgen submits MAA application for Sotorasib. Dec 24, 2020 166
Amgen submits MAA application for Sotorasib. Dec 24, 2020 162
Genprex finishes production ramp up of REQORSA ahead of lung cancer clinical trials. Dec 23, 2020 430
AstraZeneca lung cancer drug receives US regulatory green light. Dec 22, 2020 273
AstraZeneca's Tagrisso approved by FDA as adjuvant therapy for most common type of lung cancer. Dec 21, 2020 318
AstraZeneca's Tagrisso approved by FDA as adjuvant therapy for most common type of lung cancer. Dec 21, 2020 317
AstraZeneca's Tagrisso approved by FDA as adjuvant therapy for most common type of lung cancer. Dec 21, 2020 313
Imugene completes enrolment of first cohort of patients in Phase I clinical trial of checkpoint immunotherapy candidate PD1-Vaxx. Dec 18, 2020 398
Imugene completes enrolment of first cohort of patients in Phase I clinical trial of checkpoint immunotherapy candidate PD1-Vaxx. Dec 18, 2020 396
AstraZeneca's Imfinzi recommended for EU approval at new dose. Dec 15, 2020 221
AstraZeneca's Imfinzi recommended for EU approval at new dose. Dec 15, 2020 222
AstraZeneca's Imfinzi recommended for EU approval at new dose. Dec 15, 2020 217
AstraZeneca's Imfinzi Recommended By EU For NSCLC Fixed Dose Treatment. Dec 15, 2020 199
Bayer & Atara Biotherapeutics partnership leverage mesothelin-targeted CAR T-cell therapies for solid tumors. Dec 7, 2020 296
Bayer & Atara Biotherapeutics partnership leverage mesothelin-targeted CAR T-cell therapies for solid tumors. Dec 7, 2020 300
Bayer, Atara Biotherapeutics Team To Develop Solid Tumour Therapies. Dec 7, 2020 265
Imugene doses first patient in Phase 1 clinical trial of checkpoint immunotherapy candidate PD1-Vaxx for lung cancer. Dec 2, 2020 489
Imugene doses first patient in Phase 1 clinical trial of checkpoint immunotherapy candidate PD1-Vaxx for lung cancer. Dec 2, 2020 487
Genprex starts clinical trial site recruitment for upcoming Acclaim-1 study on REQORSA. Dec 1, 2020 317
Profile of Apoptotic Proteins after Curcumin Treatment by Antibody Array in H69AR Lung Cancer Cells. Ilhan, Suleyman Dec 1, 2020 4123
AstraZeneca says Imfinzi cancer treatment approved for less frequent dosing option. Nov 21, 2020 348
TOP NEWS: AstraZeneca Says New Dosing Of Imfinzi Approved In US. Nov 20, 2020 231
European Commission Approves Opdivo plus Yervoy with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer. Nov 9, 2020 424
Genprex launches new branding for its lead drug REQORSA in preparation for upcoming studies. Nov 7, 2020 170
Imugene receives FDA IND approval for phase-1 clinical trial of new checkpoint immunotherapy PD1-Vaxx in USA. Nov 3, 2020 349
Imugene receives FDA IND approval for phase-1 clinical trial of new checkpoint immunotherapy PD1-Vaxx in USA. Nov 3, 2020 347
Non-Small Cell Lung Cancer: Part I. Bohnenkamp, Susan; Lacovara, Jane Nov 1, 2020 1203
Quantitative influence of adaptive statistical iterative reconstruction on CT image histology of patients with primary colorectal cancer. Chen Yue; Li Wei; Liu Sibin Report Oct 31, 2020 3152
Influence of self-management exercise intervention on the cancer-related fatigue severity and self-management efficacy of patients with non-small cell lung cancer after operation. Zhu Xiaolin; Han Shuang; Chu Hongmei; Wang Min; Chen Sen Report Oct 31, 2020 2575
Genprex develops 'Acclaim' branding for upcoming combination lung cancer trials of its drug REQORSA. Oct 31, 2020 383
Genprex announces new branding for upcoming Reqorsa clinical trials. Oct 30, 2020 223
Arcus Biosciences to collaborate with AstraZeneca on trial for domvanalimab. Oct 29, 2020 251
Roche receives FDA approval for cobas EGFR Mutation Test v2. Oct 29, 2020 203
Verastem's new VS-6766 data published in The Lancet shows antitumor activity. Oct 28, 2020 205
Genprex promotes Eric Chapdelaine to VP of manufacturing. Oct 27, 2020 443
Kitov receives notice of allowance for U.S. patent covering NT219. Oct 27, 2020 280
Advaxis announces results from combination arm of Phase 1/2 ADXS-503 study. Oct 26, 2020 419
AnaptysBio, GlaxoSmithKline amend strategic immuno-oncology collaboration. Oct 26, 2020 441
Turning Point Therapeutics presents initial data from Phase 1 SHIELD-1 study. Oct 25, 2020 621
Mirati reports preliminary results from mutant KRAS selective inhibitor programs. Financial report Oct 25, 2020 438
Galera Therapeutics doses first patient in Phase 1/2 GRECO-1 trial. Oct 22, 2020 208
NeoImmuneTech Forges a Second Clinical Collaboration with Roche to Evaluate NT-I7 (efineptakin alfa) in Combination with PD-L1 Checkpoint Inhibitor in First-line Non-small Cell Lung Cancer. Oct 22, 2020 318
AstraZeneca says Tagrisso granted priority review in US. Oct 21, 2020 218
AstraZeneca's Tagrisso granted Priority Review by US FDA for adjuvant treatment of early-stage EGFR-mutated lung cancer. Oct 20, 2020 236
AstraZeneca's Tagrisso Gets Priority Review In US As Lung Cancer Drug. Oct 20, 2020 237
AstraZeneca's Tagrisso gets FDA acceptance for sNDA for NSCLC treatment. Oct 20, 2020 229
AstraZeneca's Tagrisso granted Priority Review by US FDA for adjuvant treatment of early-stage EGFR-mutated lung cancer. Oct 20, 2020 232
AstraZeneca's Tagrisso granted Priority Review by US FDA for adjuvant treatment of early-stage EGFR-mutated lung cancer. Oct 20, 2020 237
Merck reports 'positive' results from two KEYTRUDA studies. Clinical report Oct 16, 2020 264
OncoCyte to present new prospective data on DetermaRx. Oct 14, 2020 455
Lineage Cell Therapeutics announces preliminary results from study of VAC2. Oct 13, 2020 208
Amgen reveals positive topline Phase two results from the CodeBreaK 100 clinical study of sotorasib. Clinical report Oct 6, 2020 195
Amgen reveals positive topline Phase two results from the CodeBreaK 100 clinical study of sotorasib. Clinical report Oct 6, 2020 191
Biocept's Target Selector outperforms traditional tumor cell detection test in metastatic lung cancer study. Clinical report Oct 6, 2020 454
Zai Lab announces first patient dosed in China in Phase 3 study of retifanlimab. Clinical report Oct 5, 2020 160
Biocept provides results from Target Selector study. Clinical report Oct 5, 2020 195
Amgen reports 'positive' topline Phase 2 results from CodeBreaK 100 study. Oct 5, 2020 270
Qualigen expands AML candidate research agreement with University of Lousville. Oct 1, 2020 167
Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer. Parra, Edwin Roger; Jiang, Mei; Machado-Rugolo, Juliana; Yaegashi, Lygia Bertalha; Prieto, Tabatha; Report Oct 1, 2020 8390
BeyondSpring announces publication of manuscript on plinabulin. Sep 29, 2020 275
Calithera Biosciences initiates KEAPSAKE Phase 2 trial of telaglenastat. Sep 24, 2020 246
Biocept announces Highmark has made a positive coverage determination on Target Selector liquid biopsy. Sep 24, 2020 164
Biocept says health insurer Highmark has made a positive coverage determination on its Target Selector liquid biopsy. Sep 22, 2020 632
Sanofi And Regeneron's Libtayo Cancer Therapy Shows Promising Results. Sep 21, 2020 279
TOP NEWS: Astra's Lynparza Gets EU Ok For Ovarian And Prostate Cancer. Sep 21, 2020 229
MacroGenics announces $15M milestone triggered under Incyte agreement. Sep 21, 2020 192
Regeneron, Sanofi: Libtayo increases overall survival in NSCLC. Sep 21, 2020 182
Keytruda doubled survival rate versus chemo in certain patients NSLC. Sep 21, 2020 381
Sanofi presents trial data for investigational use of Libtayo in NSCLC. Sep 21, 2020 436
Sanofi says Libtayo reduced death risk by 32% compared to chemotherapy in trial. Sep 21, 2020 164
Analysis shows AstraZeneca Tagrisso demonstrated improvement in CNS DFS. Sep 20, 2020 232
Phase 1 cohort of sotorasib data published in New England Journal of Medicine. Sep 20, 2020 244
Innovent, Eli Lilly release results of ORIENT-12 study. Sep 20, 2020 209
TOP NEWS: Positive Results For AstraZeneca Drugs Imfinzi And Lynparza. Sep 18, 2020 727
AstraZeneca presents updated Imfinzi results from PACIFIC trial at ESMO. Sep 18, 2020 494
Blueprint Medicines' BLU-945 shows anti-tumor activity in preclinical study. Sep 17, 2020 246
BeiGene presents Phase 3 data on tislelizumab and pamiparib. Sep 17, 2020 368
Redx Pharma in busy summer with two major partnerships. Sep 15, 2020 533
Immatics provides update on IMA204 ACTengine cell therapy program. Sep 10, 2020 315
Advaxis reports Q3 EPS (9c) vs. ($1.00) last year. Financial report Sep 10, 2020 326
Genentech Wins FDA Approval of Gavreto for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer. Sep 8, 2020 769
Blueprint Medicines' GAVRETO receives US FDA approval. Sep 7, 2020 189
Blueprint Medicines' GAVRETO receives US FDA approval. Sep 7, 2020 185
US Regulator Approves Roche Lung Cancer Treatment Gavreto. Sep 7, 2020 283
Blueprint Medicines announces FDA approval of Gavreto. Sep 7, 2020 394
Imugene gets ethics approval to start Phase 1 clinical trial of immunotherapy candidate for lung cancer in the US. Sep 4, 2020 372
BeyondSpring reports Q2 EPS (32c), consensus (57c). Financial report Sep 3, 2020 157
Novartis reports published Phase 2 results of Tabrecta in NSLC. Financial report Sep 2, 2020 201
Comparison of Magnetically Responsive Trimethyl Chitosan and Chitosan Nanoparticles for Gemcitabine Delivery With in Vitro Studies. Unal, Ayse; Ak, Guliz; Sanlier, Senay Hamarat Sep 1, 2020 4356
Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Wang, Yi; Wang, Yan; Li, Jialong; Li, Jue; Che, Guowei Report Aug 31, 2020 4984
Comparison of Sleep Quality before and after Chemotherapy in Locally Advanced Nonsmall Cell Lung Cancer Patients: A Prospective Study. Belloumi, N.; Bellaj, S. Maalej; Bachouche, I.; Abdallah, F. Chermiti Ben; Fenniche, S. Clinical report Aug 31, 2020 5462
Effects of Apatinib on the "Sternness" of Non-Small-Cell Lung Cancer Cells In Vivo and Its Related Mechanisms. Yang, Bin; Wang, Yan; Chen, Zhuoying; Feng, Yi-Ming; Shi, Liang-Liang Aug 31, 2020 3514
Relationship between SP142 PD-L1 Expression and [sup.18]F-FDG Uptake in Non-Small-Cell Lung Cancer. Zhao, Long; Liu, Jinjun; Shi, Jingyun; Wang, Huoqiang Aug 31, 2020 7254
The Role of CTHRC1 in Regulation of Multiple Signaling and Tumor Progression and Metastasis. Mei, Dan; Zhu, Yue; Zhang, Lingling; Wei, Wei Aug 31, 2020 11007
2-(6-Hydroxyhexylthio)-5,8-dimethoxy-1,4-naphthoqiiinone Induces Aprahrsis hprrqgp ROS-Mediahed MAPK, STAT3, and NF-[kappa]B Signalling Pathways in Lung Cancer A549 Cells. Shen, Gui-Nan; Wang, Cheng; Luo, Ying-Hua; Wang, Jia-Ru; Wang, Rui; Xu, Wan-Ting; Zhang, Yi; Zhang, Aug 31, 2020 6280
Euglycemic Ketoacidosis in a Patient with Metastatic Non-Small-Cell Lung Adenocarcinoma and Concomitant Pulmonary Embolism. O'Neill, Robert Sean; Tyack, Lauren; Freeman, Mary; Hussein, Hussein Soudy Aug 31, 2020 1927
4D pharma soars after it says combination therapy "far exceeds" success threshold in early stage cancer trial. Aug 27, 2020 594
Proactive news headlines: 4D pharma, EQTEC, Iofina, Blue Star Capital ... Aug 27, 2020 1790
Eli Lilly announces Retevmo data published in NEJM. Aug 27, 2020 537
Bio-Thera Solutions, BeiGene Ink License, Distribution, and Supply Agreement for Avastin Biosimilar BAT1706 in China. Aug 24, 2020 370
BeiGene enters license, distribution, supply agreement with Bio-Thera Solutions. Aug 24, 2020 167
AstraZeneca's Imfinzi Gets US Review That Could Halve Medical Visits. Aug 18, 2020 248
Thermo Fisher signs companion diagnostic agreement with Hengrui Therapeutics. Aug 17, 2020 251
ANGLE highlights research showing potential for Parsortix to assess patient response to immunotherapy. Aug 15, 2020 448
Angle's Parsortix Able To Predict Patients' Response To Treatment. Aug 14, 2020 259
Daiichi Sankyo Forges Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer. Aug 11, 2020 725
OncoCyte to hold KOL webinar on DetermaIO clinical data. Aug 11, 2020 168
Bristol-Myers says Health Canada approves Opdivo-Yervoy combo. Aug 11, 2020 197
Innovent, Lilly announce interim analysis data from ORIENT-11. Aug 9, 2020 256
Guardant Health announces FDA approval for Guardant360 CDx for CGP. Aug 7, 2020 201

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |